Lilly takes on Pfizer, Novartis with new breast cancer drug data

NEW YORK/MADRID (Reuters) - Eli Lilly staked its claim for a slice of sales in a new class of breast cancer drugs on Sunday as clinical data showed adding its medicine abemaciclib to standard therapy reduced the risk of disease progression by 46 percent.